Skip to main content

Table 3 Calculated parameters for the ability of the refined (26-gene) GEPR to predict disease control

From: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Parameter

KRAS-wildtype

All patients

KRAS-mutant

Specificity

0.74

0.71

0.78

Sensitivity

0.80

0.80

1.00

PPV

0.76

0.63

0.33

NPV

0.78

0.86

1.00

  1. NPV: negative predictive value; PPV positive predictive value
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us